BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019;92:170-92. [PMID: 30391259 DOI: 10.1016/j.metabol.2018.10.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Woodard K, Louque L, Hsia DS. Medications for the treatment of obesity in adolescents. Therapeutic Advances in Endocrinology 2020;11:204201882091878. [DOI: 10.1177/2042018820918789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Farr OM, Pilitsi E, Mantzoros CS. Of mice and men: incretin actions in the central nervous system. Metabolism 2019;98:121-35. [PMID: 31173757 DOI: 10.1016/j.metabol.2019.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dhurandhar NV, Petersen KS, Webster C. Key Causes and Contributors of Obesity: A Perspective. Nurs Clin North Am 2021;56:449-64. [PMID: 34749887 DOI: 10.1016/j.cnur.2021.07.007] [Reference Citation Analysis]
4 Zhuoyue Z, Ruangaram W, Kato E. Saponins are responsible for the anti-obesogenic activity of Acacia concinna. J Nat Med 2021;75:1005-13. [PMID: 34019225 DOI: 10.1007/s11418-021-01530-0] [Reference Citation Analysis]
5 Boutari C, Polyzos SA, Mantzoros CS. Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it? Metabolism 2019;96:vi-xi. [DOI: 10.1016/j.metabol.2019.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Li M, Xiao Y, Xiao L, Li Y, Jia M, Sun Y, Pan T, Zhou L, Li Y. Epigoitrin alleviates lipid and glucose metabolic disorders induced by a high-fat diet. Food Funct 2022. [PMID: 35723416 DOI: 10.1039/d2fo00242f] [Reference Citation Analysis]
7 Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (Torino) 2021;46:168-76. [PMID: 33213122 DOI: 10.23736/S2724-6507.20.03369-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Casu A, Bilal A, Pratley RE; Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON). Pharmacological therapies to address obesity in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:194-206. [PMID: 32618631 DOI: 10.1097/MED.0000000000000555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Dent R, Mcpherson R, Harper M. Factors affecting weight loss variability in obesity. Metabolism 2020;113:154388. [DOI: 10.1016/j.metabol.2020.154388] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
10 Lin CH, Shao L, Zhang YM, Tu YJ, Zhang Y, Tomlinson B, Chan P, Liu Z. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother 2020;21:275-85. [PMID: 31790314 DOI: 10.1080/14656566.2019.1695779] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int 2021;41:1853-66. [PMID: 33788377 DOI: 10.1111/liv.14888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Li Y, Tao Y, Gao X, Yu F. Case Report: Bilateral Ciliary Body Detachment in a Patient Taking Oral Diet Pills. Optom Vis Sci 2021;98:876-80. [PMID: 34460449 DOI: 10.1097/OPX.0000000000001743] [Reference Citation Analysis]
13 García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, Soler MJ. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. Front Med (Lausanne) 2021;8:655871. [PMID: 33928108 DOI: 10.3389/fmed.2021.655871] [Reference Citation Analysis]
14 Perakakis N, Kokkinos A, Angelidi AM, Tsilingiris D, Gavrieli A, Yannakoulia M, Tentolouris N, Mantzoros CS. Changes in circulating levels of five proglucagon-derived peptides in response to intravenous or oral administration of glucose and lipids and in response to a mixed-meal in subjects with normal weight, overweight, and obesity. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.07.001] [Reference Citation Analysis]
15 Widiarti W, Sukmajaya AC, Nugraha D, Alkaff FF. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review. Diabetes Metab Syndr 2021;15:837-43. [PMID: 33866119 DOI: 10.1016/j.dsx.2021.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gavini CK, Cook TM, Rademacher DJ, Mansuy-Aubert V. Hypothalamic C2-domain protein involved in MC4R trafficking and control of energy balance. Metabolism 2020;102:153990. [PMID: 31666192 DOI: 10.1016/j.metabol.2019.153990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
17 Kato E, Tsuruma A, Amishima A, Satoh H. Proteinous pancreatic lipase inhibitor is responsible for the antiobesity effect of young barley (Hordeum vulgare L.) leaf extract. Biosci Biotechnol Biochem 2021;85:1885-9. [PMID: 34048530 DOI: 10.1093/bbb/zbab096] [Reference Citation Analysis]
18 Ji L, Jiang H, An P, Deng H, Liu M, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine 2021;39:101088. [PMID: 34430840 DOI: 10.1016/j.eclinm.2021.101088] [Reference Citation Analysis]
19 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
20 Wang C, Jiang X, Zeng Y, Terry RN, Li W. Rapidly separable microneedle patches for controlled release of therapeutics for long-acting therapies. Medicine in Drug Discovery 2021. [DOI: 10.1016/j.medidd.2021.100118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int J Mol Sci 2021;22:6332. [PMID: 34199317 DOI: 10.3390/ijms22126332] [Reference Citation Analysis]
22 Park J, Kim HL, Jung Y, Ahn KS, Kwak HJ, Um JY. Bitter Orange (Citrus aurantium Linné) Improves Obesity by Regulating Adipogenesis and Thermogenesis through AMPK Activation. Nutrients 2019;11:E1988. [PMID: 31443565 DOI: 10.3390/nu11091988] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
23 Král J, Machytka E, Horká V, Selucká J, Doleček F, Špičák J, Kovářová V, Haluzík M, Bužga M. Endoscopic Treatment of Obesity and Nutritional Aspects of Bariatric Endoscopy. Nutrients 2021;13:4268. [PMID: 34959819 DOI: 10.3390/nu13124268] [Reference Citation Analysis]
24 Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep 2021;11:5637. [PMID: 33707534 DOI: 10.1038/s41598-021-85051-6] [Reference Citation Analysis]
25 Jeong D, Priefer R. Anti-obesity weight loss medications: Short-term and long-term use. Life Sci 2022;306:120825. [PMID: 35870619 DOI: 10.1016/j.lfs.2022.120825] [Reference Citation Analysis]
26 Wiechert M, Holzapfel C. Nutrition Concepts for the Treatment of Obesity in Adults. Nutrients 2021;14:169. [PMID: 35011045 DOI: 10.3390/nu14010169] [Reference Citation Analysis]
27 Singhal V, Sella AC, Malhotra S. Pharmacotherapy in pediatric obesity: current evidence and landscape. Curr Opin Endocrinol Diabetes Obes 2021;28:55-63. [PMID: 33186194 DOI: 10.1097/MED.0000000000000587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
28 Arastu N, Cummins O, Uribe W, Nemec EC. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. Int J Clin Pharm 2022. [PMID: 35715543 DOI: 10.1007/s11096-022-01428-1] [Reference Citation Analysis]
29 Peradze N, Farr OM, Mantzoros CS. Research developments in metabolism 2018. Metabolism 2019;91:70-9. [PMID: 30503805 DOI: 10.1016/j.metabol.2018.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Gowda S, Seibert T, Uli N, Farrell R. Pediatric Obesity: Endocrinologic and Genetic Etiologies and Management. Curr Cardiovasc Risk Rep 2019;13. [DOI: 10.1007/s12170-019-0632-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Weizman S, Shelef A, Bloemhof Bris E, Stryjer R. A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia. J Clin Psychopharmacol 2021;41:629-31. [PMID: 34735098 DOI: 10.1097/JCP.0000000000001481] [Reference Citation Analysis]
32 Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf 2020;19:1095-104. [PMID: 32750250 DOI: 10.1080/14740338.2020.1806234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zemel MB. Medicinal Foods and Obesity. J Med Food 2020;23:203-4. [PMID: 32058827 DOI: 10.1089/jmf.2020.29005.mbz] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Ullah H, Sommella E, Santarcangelo C, D'Avino D, Rossi A, Dacrema M, Minno AD, Di Matteo G, Mannina L, Campiglia P, Magni P, Daglia M. Hydroethanolic Extract of Prunus domestica L.: Metabolite Profiling and In Vitro Modulation of Molecular Mechanisms Associated to Cardiometabolic Diseases. Nutrients 2022;14:340. [PMID: 35057523 DOI: 10.3390/nu14020340] [Reference Citation Analysis]
35 Perakakis N, Mantzoros CS. The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions. The Journal of Clinical Endocrinology & Metabolism 2020;105:e3003-5. [DOI: 10.1210/clinem/dgaa329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
36 Ryan DH. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? J Obes Metab Syndr 2021;30:196-208. [PMID: 34518444 DOI: 10.7570/jomes21033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
37 Huang D, Deng M, Kuang S. Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment. Trends Endocrinol Metab 2019;30:974-89. [PMID: 31668904 DOI: 10.1016/j.tem.2019.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
38 Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich S. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep 2022;12:484. [PMID: 35013352 DOI: 10.1038/s41598-021-03670-5] [Reference Citation Analysis]
39 Czepiel KS, Perez NP, Campoverde Reyes KJ, Sabharwal S, Stanford FC. Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US. Front Endocrinol (Lausanne) 2020;11:290. [PMID: 32477270 DOI: 10.3389/fendo.2020.00290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
40 Atchan Nwakiban AP, Sokeng AJ, Dell'agli M, Bossi L, Beretta G, Gelmini F, Deutou Tchamgoue A, Agbor Agbor G, Kuiaté J, Daglia M, Magni P. Hydroethanolic plant extracts from Cameroon positively modulate enzymes relevant to carbohydrate/lipid digestion and cardio-metabolic diseases. Food Funct 2019;10:6533-42. [DOI: 10.1039/c9fo01664c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Van Prooyen AM, Hicks JL, Lin E, Davis SS Jr, Singh A, Harris DA, Falconer EA, Hechenbleikner EM. Evaluation of An Inpatient Pharmacy Consult on Discharge Medications in Bariatric Surgery Patients. J Pharm Pract 2021;:8971900211030238. [PMID: 34227420 DOI: 10.1177/08971900211030238] [Reference Citation Analysis]
42 Yin M, Song Y, Guo S, Zhang X, Sun K, Li Y, Shi Y. Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers. Mol Pharm 2020;17:1899-909. [PMID: 32267705 DOI: 10.1021/acs.molpharmaceut.9b01307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Son JW, Kim S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J 2020;44:802-18. [PMID: 33389955 DOI: 10.4093/dmj.2020.0258] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
44 Alruwaili H, Dehestani B, le Roux CW. Clinical Impact of Liraglutide as a Treatment of Obesity. Clin Pharmacol 2021;13:53-60. [PMID: 33732030 DOI: 10.2147/CPAA.S276085] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Gouni-Berthold I, Berthold HK. Current Options for the Pharmacotherapy of Obesity. Curr Pharm Des 2019;25:2019-32. [PMID: 31298150 DOI: 10.2174/1381612825666190708192630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Med Clin North Am 2021;105:983-1016. [PMID: 34688422 DOI: 10.1016/j.mcna.2021.06.005] [Reference Citation Analysis]
47 Nguyen PTV, Huynh HA, Truong DV, Tran TD, Vo CT. Exploring Aurone Derivatives as Potential Human Pancreatic Lipase Inhibitors through Molecular Docking and Molecular Dynamics Simulations. Molecules 2020;25:E4657. [PMID: 33066044 DOI: 10.3390/molecules25204657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Peterman DE, Warren JA. Ventral Hernia Management in Obese Patients. Surg Clin North Am 2021;101:307-21. [PMID: 33743971 DOI: 10.1016/j.suc.2020.12.014] [Reference Citation Analysis]
49 Li X, Wei T, Wu M, Chen F, Zhang P, Deng ZY, Luo T. Potential metabolic activities of raspberry ketone. J Food Biochem 2021;:e14018. [PMID: 34913499 DOI: 10.1111/jfbc.14018] [Reference Citation Analysis]
50 Schrader TO, Zhu X, Kasem M, Ren A, Liu C, Wu C, Dang H, Le M, Gatlin J, Chase K, Frazer J, Whelan KT, Grottick AJ, Hutton C, Barden J, Chen C, Ortiz A, Feichtinger K, Semple G. Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT2C receptor. Bioorg Med Chem Lett 2021;38:127872. [PMID: 33636307 DOI: 10.1016/j.bmcl.2021.127872] [Reference Citation Analysis]
51 Esakkimuthu S, Nagulkumar S, Darvin SS, Buvanesvaragurunathan K, Sathya TN, Navaneethakrishnan KR, Kumaravel TS, Murugan SS, Shirota O, Balakrishna K, Pandikumar P, Ignacimuthu S. Antihyperlipidemic effect of iridoid glycoside deacetylasperulosidic acid isolated from the seeds of Spermacoce hispida L. - A traditional antiobesity herb. J Ethnopharmacol 2019;245:112170. [PMID: 31434002 DOI: 10.1016/j.jep.2019.112170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Cifuentes L, Camilleri M, Acosta A. Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications. Nutrients 2021;13:1158. [PMID: 33915747 DOI: 10.3390/nu13041158] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Kokkinos A, Tsilingiris D, le Roux CW, Rubino F, Mantzoros CS. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery? Metabolism 2019;100:153960. [PMID: 31412266 DOI: 10.1016/j.metabol.2019.153960] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
54 Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021;13:351. [PMID: 33503878 DOI: 10.3390/nu13020351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab 2020;11:2042018819897527. [PMID: 32030121 DOI: 10.1177/2042018819897527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
56 Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, Chapman CG, Popov V, Jirapinyo P, Acosta A, Vargas EJ, Storm AC, Bazerbachi F, Ryou M, French M, Noria S, Molina D, Thompson CC. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021;398:1965-73. [PMID: 34793746 DOI: 10.1016/S0140-6736(21)02394-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Investig Drugs 2019;28:1081-94. [PMID: 31714807 DOI: 10.1080/13543784.2019.1692813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
58 Ryan DH. Semaglutide for obesity: four STEPs forward, but more to come. Lancet Diabetes Endocrinol 2021;9:252-4. [PMID: 33864806 DOI: 10.1016/S2213-8587(21)00081-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
59 Shen Y, Shi Z, Yan B. Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and other Transcription Factors. Nuclear Receptor Research 2019;6. [DOI: 10.32527/2019/101435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
60 Kuo HH, Wang KT, Lee YH, Lin PL, Liu ME, Lin CY, Liu LY. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. J Clin Pharm Ther 2020;45:35-44. [PMID: 31544267 DOI: 10.1111/jcpt.13047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Gutt S, Schraier S, González Bagnes MF, Yu M, González CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother 2019;20:939-47. [PMID: 30882259 DOI: 10.1080/14656566.2019.1583746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Briand F, Brousseau E, Maupoint J, Dubroca C, Costard C, Breyner N, Burcelin R, Sulpice T. Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model. European Journal of Pharmacology 2020;882:173316. [DOI: 10.1016/j.ejphar.2020.173316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Li Z, Fang X, Yu D. Transdermal Drug Delivery Systems and Their Use in Obesity Treatment. Int J Mol Sci 2021;22:12754. [PMID: 34884558 DOI: 10.3390/ijms222312754] [Reference Citation Analysis]
64 Li H, Wang C, Li L, Li L. Skeletal muscle non-shivering thermogenesis as an attractive strategy to combat obesity. Life Sci 2021;269:119024. [PMID: 33450257 DOI: 10.1016/j.lfs.2021.119024] [Reference Citation Analysis]
65 Peradze N, Farr OM, Perakakis N, Lázaro I, Sala-Vila A, Mantzoros CS. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc Diabetol 2019;18:141. [PMID: 31672146 DOI: 10.1186/s12933-019-0945-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
66 Koliaki C, Liatis S, Dalamaga M, Kokkinos A. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. Curr Obes Rep 2020;9:255-71. [PMID: 32647952 DOI: 10.1007/s13679-020-00396-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Chang Y, Zhang D, Yang G, Zheng Y, Guo L. Screening of Anti-Lipase Components of Artemisia argyi Leaves Based on Spectrum-Effect Relationships and HPLC-MS/MS. Front Pharmacol 2021;12:675396. [PMID: 34025435 DOI: 10.3389/fphar.2021.675396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Gray JC, Schvey NA, Tanofsky-Kraff M. Demographic, psychological, behavioral, and cognitive correlates of BMI in youth: Findings from the Adolescent Brain Cognitive Development (ABCD) study. Psychol Med 2020;50:1539-47. [PMID: 31288867 DOI: 10.1017/S0033291719001545] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
69 Anekwe CV, Knight MG, Seetharaman S, Dutton WP, Chhabria SM, Stanford FC. Pharmacotherapeutic options for weight regain after bariatric surgery. Curr Treat Options Gastroenterol 2021;19:524-41. [PMID: 34511864 DOI: 10.1007/s11938-021-00358-7] [Reference Citation Analysis]
70 Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, Taveras EM, Corey K, Kaplan L, Hur C. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2020;6:162-70. [PMID: 32313674 DOI: 10.1002/osp4.390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
71 Trujillo-Viera J, El-Merahbi R, Schmidt V, Karwen T, Loza-Valdes A, Strohmeyer A, Reuter S, Noh M, Wit M, Hawro I, Mocek S, Fey C, Mayer AE, Löffler MC, Wilhelmi I, Metzger M, Ishikawa E, Yamasaki S, Rau M, Geier A, Hankir M, Seyfried F, Klingenspor M, Sumara G. Protein Kinase D2 drives chylomicron-mediated lipid transport in the intestine and promotes obesity. EMBO Mol Med 2021;13:e13548. [PMID: 33949105 DOI: 10.15252/emmm.202013548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Xu L, Xu C, Liu X, Li X, Li T, Yu X, Xue M, Yang J, Kosmas CE, Moris D, Sanchis-Gomar F, Yoshida N, Berger NA, Aronow WS, Sun B, Chen L. Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes. Front Physiol 2021;12:745058. [PMID: 34777009 DOI: 10.3389/fphys.2021.745058] [Reference Citation Analysis]
73 Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep 2021;10:14-30. [PMID: 33410104 DOI: 10.1007/s13679-020-00422-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
74 Ammori BJ, Skarulis MC, Soran H, Syed AA, Eledrisi M, Malik RA. Medical and surgical management of obesity and diabetes: what's new? Diabet Med 2020;37:203-10. [PMID: 31850536 DOI: 10.1111/dme.14215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
75 Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: An update. Pharmacol Res 2021;169:105649. [PMID: 33962014 DOI: 10.1016/j.phrs.2021.105649] [Reference Citation Analysis]
76 Schnabl K, Li Y, U-Din M, Klingenspor M. Secretin as a Satiation Whisperer With the Potential to Turn into an Obesity-curbing Knight. Endocrinology 2021;162:bqab113. [PMID: 34089599 DOI: 10.1210/endocr/bqab113] [Reference Citation Analysis]
77 Zhang H, Chen S. Cyclic peptide drugs approved in the last two decades (2001–2021). RSC Chem Biol 2022;3:18-31. [DOI: 10.1039/d1cb00154j] [Reference Citation Analysis]
78 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 29.0] [Reference Citation Analysis]
79 Huang D, Narayanan N, Cano-Vega MA, Jia Z, Ajuwon KM, Kuang S, Deng M. Nanoparticle-Mediated Inhibition of Notch Signaling Promotes Mitochondrial Biogenesis and Reduces Subcutaneous Adipose Tissue Expansion in Pigs. iScience 2020;23:101167. [PMID: 32480124 DOI: 10.1016/j.isci.2020.101167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
80 Xu XY, Zhao CN, Li BY, Tang GY, Shang A, Gan RY, Feng YB, Li HB. Effects and mechanisms of tea on obesity. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34704503 DOI: 10.1080/10408398.2021.1992748] [Reference Citation Analysis]
81 Gutman R, Rauch M, Neuman A, Khamaisi H, Jonas-Levi A, Konovalova Y, Rytwo G. Sepiolite Clay Attenuates the Development of Hypercholesterolemia and Obesity in Mice Fed a High-Fat High-Cholesterol Diet. J Med Food 2020;23:289-96. [PMID: 31580748 DOI: 10.1089/jmf.2019.0030] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Bromek E, Rysz M, Haduch A, Daniel WA. Stimulation of 5-HT2C serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver. Pharmacol Rep 2019;71:1210-2. [PMID: 31671379 DOI: 10.1016/j.pharep.2019.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev 2021:bnab034. [PMID: 34698815 DOI: 10.1210/endrev/bnab034] [Reference Citation Analysis]
84 Perakakis N, Farr OM, Mantzoros CS. Leptin in Leanness and Obesity: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:745-60. [PMID: 33573745 DOI: 10.1016/j.jacc.2020.11.069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
85 Stubbs RJ, Duarte C, O'Driscoll R, Turicchi J, Kwasnicka D, Sniehotta FF, Marques MM, Horgan G, Larsen S, Palmeira A, Santos I, Teixeira PJ, Halford J, Heitmann BL; The EASO Obesity Management Task Force. The H2020 "NoHoW Project": A Position Statement on Behavioural Approaches to Longer-Term Weight Management. Obes Facts 2021;14:246-58. [PMID: 33662958 DOI: 10.1159/000513042] [Reference Citation Analysis]